Centre For Clinical Research And Biostatistics (CCRB)

Back History

1 Unique Trial Number (assigned by CCRB)

CUHK_CCT00076

2 Trial Registration Date

2005-09-21

iRegistration Status

Retrospective

3 Secondary IDs

Not applicable

4 Source(s) of Funding

N/A

5 Primary Sponsor

Nil

6 Secondary Sponsor

Nil

Function

Please specify

7Responsible Contact Person (public contact person for patients interested in participating)

i Name

Miss Joyce Kung

ii Address

3/F, Hong Kong Eye Hospital, 147K Argyle Street, Kowloon

iii Phone

27623134

iv Email

joycekung@cuhk.edu.hk

v Affiliation

Department of Ophthalmology & Visual Sciences, The Chinese University of Hong Kong

vi Country

8Research Contact Person (person to contact for scientific inquiries)

i Name

Prof. Dennis SC Lam

ii Address

3/F, Hong Kong Eye Hospital, 147K Argyle Street, Kowloon.

iii Phone

27623134

iv Email

dennislam_cu_res@cuhk.edu.hk

v Affiliation

Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong

vi Country

9 Official Scientific Title of the Study

A Randomized Controlled Trial to Compare the Safety and Efficacy of Intravitreal Triamcinolone Versus Combined Triamcinolone and Grid Laser Versus Observation in the Treatment of Macular Edema Associated With Central Retinal Vein Occlusion

10 Public Title

A Randomized Controlled Trial to Compare the Safety and Efficacy of Intravitreal Triamcinolone Versus Combined Triamcinolone and Grid Laser Versus Observation in the Treatment of Macular Edema Associated With Central Retinal Vein Occlusion

i Public Title in Chinese 研究名稱

11 Short Title (Optional)

Nil

12 Countries of Recruitment

Hong Kong

13Research Ethic Review

i Has the study received appropriate ethics approval?

Yes

ii When is the approval date?

2004-01-04

iii Full Name of IRB/IEC

Please specify

iv IRB/IEC approval reference number

14 Medical Condition Being Studied

Eye Diseases

15Intervention

i Types of intervention

Procedure

Please specify

ii Description/ name of Intervention/article

Treatment of macular edema secondary to CRVO with ivTA with laser

iii Dosage form of the intervention

iv Dosage of the intervention

v Duration of the intervention

30 months

vi Frequency of the intervention

16Comparative Treatments

i Description/ name of comparative treatments

Treatment of macular edema secondary to CRVO with ivTA without laser

ii Dosage form of the comparative treatments

iii Dosage of the comparative treatments

iv Duration of the comparative treatments

v Frequency of the comparative treatments

17Key Inclusion and Exclusion Criteria

i Inclusion Criteria

Inclusion criteria: 1. Age of at least 18 years; 2. Visual acuity 20/50 or poorer; 3. Macular edema of at least 250µm involving the fovea, as documented on optical coherent tomogram 4. Patients with best corrected visual acuity of better than 1.7 ETDRS logMar units; 5. Patients physically fit to receive laser photocoagulation or intravitreal injection; 6. Informed consent

ii Exclusion Criteria

Exclusion criteria
1.Previous photocoagulation for retinal vascular disease of study eye;
2. Intercurrent eye disease except cataract and refractive error that is likely to affect visual acuity over study period;
3.Glaucoma and history of ocular hypertension;
4.Presence of peripheral anterior synechia in the study case;
5.Media opacities which affect fundus examination or OCT measurements;
6.Previous intraocular surgery except uncomplicated cataract extraction and posterior intraocular lens insertion;
7.Any cataract extraction or laser procedure within 3 months;
8.Pregnant patients;
9.Failure to comply with follow up schedule

iii Age Minimum

18

iv Age Maximum

None set

v Gender

Both Male and Female

18 Study Type

Interventional

19Study Design

i Randomization

Randomized

Please specify

ii Nature of control

Active

iii Degree of masking

Open label

If Single-blind, who will be masked?

iv Group Assignment

Parallel

v Study Phase

Please specify

vi Study Objectives (Optional)

20 Anticipated trial start date

2005-01-15

21 Target Sample Size

300

22 Recruitment Status

Complete

23 Primary Outcome

Best-corrected visual acuity (ETDRS chart)

24 Secondary Outcome

1. Macular edema 2. Intraocular pressure 3. Degree of cataract assessed clinically 4. To measure the level of vascular endothelial growth factor in the vitreous at the time of treatment

25Study Information/Publication

i Study Information/Publication Available?

No

ii Link to Study Information/Publication

26Last Update Date

2013-01-14

27 Primary Registry and Trial Identifying Number

ChiCTR-TRC-05000661

28 Date of Registration in Primary Registry

2010-05-04

Back History

Trial Detail